TY - JOUR
T1 - p53 and bladder cancer
AU - li, William W.
AU - li, Vincent W.
AU - Tsakayannis, Dimitris
AU - Xing, Xueping
AU - Wood, Lowell L.
AU - Cote, Richard J.
AU - Skinner, Donald G.
AU - Jones, Peter A.
PY - 1995/4/6
Y1 - 1995/4/6
N2 - To the Editor: Esrig and colleagues (Nov. 10 issue)1 demonstrate that the immunohistochemical detection of p53 protein in bladder-tumor cells predicts the progression of disease independently of the tumor stage and histologic grade and correlates with an increased risk of recurrent tumor and mortality. This work, combined with recent advances such as the purification of angiostatin, an endogenous inhibitor of tumor angiogenesis,2 foreshadows a new approach to identifying patients at high risk for recurrence and metastases, especially when lymph nodes appear to be uninvolved and when surgical resection of the primary tumor suggests an initial cure. Such patients may benefit.
AB - To the Editor: Esrig and colleagues (Nov. 10 issue)1 demonstrate that the immunohistochemical detection of p53 protein in bladder-tumor cells predicts the progression of disease independently of the tumor stage and histologic grade and correlates with an increased risk of recurrent tumor and mortality. This work, combined with recent advances such as the purification of angiostatin, an endogenous inhibitor of tumor angiogenesis,2 foreshadows a new approach to identifying patients at high risk for recurrence and metastases, especially when lymph nodes appear to be uninvolved and when surgical resection of the primary tumor suggests an initial cure. Such patients may benefit.
UR - http://www.scopus.com/inward/record.url?scp=0029637616&partnerID=8YFLogxK
U2 - 10.1056/NEJM199504063321413
DO - 10.1056/NEJM199504063321413
M3 - Letter
C2 - 7877657
AN - SCOPUS:0029637616
SN - 0028-4793
VL - 332
SP - 957
EP - 958
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 14
ER -